RASopathies: unraveling mechanisms with animal models

被引:60
作者
Jindal, Granton A. [1 ,2 ]
Goyal, Yogesh [1 ,2 ]
Burdine, Rebecca D. [3 ]
Rauen, Katherine A. [4 ]
Shvartsman, Stanislav Y. [1 ,2 ,3 ]
机构
[1] Princeton Univ, Dept Chem & Biol Engn, Princeton, NJ 08544 USA
[2] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA
[3] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA
[4] Univ Calif Davis, Div Genom Med, MIND Inst, Dept Pediat, Sacramento, CA 95817 USA
基金
美国国家卫生研究院;
关键词
Ras-MAPK; Developmental disorders; Drosophila; Zebrafish; Mice; Drug target; NEUROFIBROMATOSIS TYPE-1 GENE; OF-FUNCTION MUTATIONS; GAP-RELATED DOMAIN; MOUSE MODEL; NOONAN-SYNDROME; COSTELLO-SYNDROME; TUMOR-SUPPRESSOR; GLIOMA FORMATION; MEK INHIBITION; DEVELOPMENTAL DEFECTS;
D O I
10.1242/dmm.020339
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
RASopathies are developmental disorders caused by germline mutations in the Ras-MAPK pathway, and are characterized by a broad spectrum of functional and morphological abnormalities. The high incidence of these disorders (similar to 1/1000 births) motivates the development of systematic approaches for their efficient diagnosis and potential treatment. Recent advances in genome sequencing have greatly facilitated the genotyping and discovery of mutations in affected individuals, but establishing the causal relationships between molecules and disease phenotypes is non-trivial and presents both technical and conceptual challenges. Here, we discuss how these challenges could be addressed using genetically modified model organisms that have been instrumental in delineating the Ras-MAPK pathway and its roles during development. Focusing on studies in mice, zebrafish and Drosophila, we provide an up-to-date review of animal models of RASopathies at the molecular and functional level. We also discuss how increasingly sophisticated techniques of genetic engineering can be used to rigorously connect changes in specific components of the Ras-MAPK pathway with observed functional and morphological phenotypes. Establishing these connections is essential for advancing our understanding of RASopathies and for devising rational strategies for their management and treatment.
引用
收藏
页码:769 / U403
页数:30
相关论文
共 202 条
[1]   Lovastatin as Treatment for Neurocognitive Deficits Type 1: Phase I Study [J].
Acosta, Maria T. ;
Kardel, Peter G. ;
Walsh, Karin S. ;
Rosenbaum, Kenneth N. ;
Gioia, Gerard A. ;
Packer, Roger J. .
PEDIATRIC NEUROLOGY, 2011, 45 (04) :241-245
[2]   NOONAN SYNDROME [J].
ALLANSON, JE .
JOURNAL OF MEDICAL GENETICS, 1987, 24 (01) :9-13
[3]   Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish [J].
Anastasaki, Corina ;
Rauen, Katherine A. ;
Patton, E. Elizabeth .
DISEASE MODELS & MECHANISMS, 2012, 5 (04) :546-552
[4]   Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors [J].
Anastasaki, Corina ;
Estep, Anne L. ;
Marais, Richard ;
Rauen, Katherine A. ;
Patton, E. Elizabeth .
HUMAN MOLECULAR GENETICS, 2009, 18 (14) :2543-2554
[5]   The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway [J].
Andreadi, Catherine ;
Cheung, Lai-Kay ;
Giblett, Susan ;
Patel, Bipin ;
Jin, Hong ;
Mercer, Kathryn ;
Kamata, Tamihiro ;
Lee, Pearl ;
Williams, Alexander ;
McMahon, Martin ;
Marais, Richard ;
Pritchard, Catrin .
GENES & DEVELOPMENT, 2012, 26 (17) :1945-1958
[6]   The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders [J].
Aoki, Yoko ;
Niihori, Tetsuya ;
Narumi, Yoko ;
Kure, Shigeo ;
Matsubara, Yoichi .
HUMAN MUTATION, 2008, 29 (08) :992-1006
[7]   Gain-of-Function Mutations in RIT1 Cause Noonan Syndrome, a RAS/MAPK Pathway Syndrome [J].
Aoki, Yoko ;
Niihori, Tetsuya ;
Banjo, Toshihiro ;
Okamoto, Nobuhiko ;
Mizuno, Seiji ;
Kurosawa, Kenji ;
Ogata, Tsutomu ;
Takada, Fumio ;
Yano, Michihiro ;
Ando, Toru ;
Hoshika, Tadataka ;
Barnett, Christopher ;
Ohashi, Hirofumi ;
Kawame, Hiroshi ;
Hasegawa, Tomonobu ;
Okutani, Takahiro ;
Nagashima, Tatsuo ;
Hasegawa, Satoshi ;
Funayama, Ryo ;
Nagashima, Takeshi ;
Nakayama, Keiko ;
Inoue, Shin-ichi ;
Watanabe, Yusuke ;
Ogura, Toshihiko ;
Matsubara, Yoichi .
AMERICAN JOURNAL OF HUMAN GENETICS, 2013, 93 (01) :173-180
[8]   Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation [J].
Araki, T ;
Mohi, MG ;
Ismat, FA ;
Bronson, RT ;
Williams, IR ;
Kutok, JL ;
Yang, WT ;
Pao, LI ;
Gilliland, DG ;
Epstein, JA ;
Neel, BG .
NATURE MEDICINE, 2004, 10 (08) :849-857
[9]   Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation [J].
Araki, Toshiyuki ;
Chan, Gordon ;
Newbigging, Susan ;
Morikawa, Lily ;
Bronson, Roderick T. ;
Neel, Benjamin G. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (12) :4736-4741
[10]   Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation [J].
Bajenaru, ML ;
Zhu, Y ;
Hedrick, NM ;
Donahoe, J ;
Parada, LF ;
Gutmann, DH .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (14) :5100-5113